<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096795</url>
  </required_header>
  <id_info>
    <org_study_id>D9180C00001</org_study_id>
    <nct_id>NCT03096795</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of MEDI3506 in Healthy Subjects and in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects With a History of Mild Atopy and as Multiple Ascending Doses in Subjects COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the
      safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple
      doses of MEDI3506.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the
      safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple
      doses of MEDI3506 administered by either SC or IV routes.

      Part I: Single Ascending Doses in Healthy Subjects with a History of Mild Atopy

      Part II: Multiple Ascending Doses in Subjects with GOLD I-II COPD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI3506 by assessment of adverse events</measure>
    <time_frame>Post dosing (Day 1) to end of safety follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>To assess the number Treatment Emergent Adverse events (TEAEs), Serious Adverse Events (SAEs), Treatment Emergent Adverse Events of Special Interest (AESIs),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI3506 by assessment of vital signs</measure>
    <time_frame>Post dosing (Day 1) to end of safety follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>To assess systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, 12-lead electrocardiogram and physical exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI3506 by clinical laboratory evaluations</measure>
    <time_frame>Post dosing (Day 1) to end of safety follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>To assess hematology, serum chemistry and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of the maximum observed serum drug concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of area under the concentration-time curve from 0 to infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of terminal half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of apparent clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the presence of anti-drug antibodies (ADAs) to MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Immunogenicity of MEDI3506 by the measurement of anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of the time to maximum observed serum drug concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of MEDI3506</measure>
    <time_frame>Post dosing (Day 1) to end of follow-up (i.e. SAD Cohorts 1-7: Day 169; MAD Cohorts 1-3: Day 169)</time_frame>
    <description>Pharmacokinetics of MEDI3506 by assessment of volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Safety</condition>
  <condition>Part I (SAD) - Healthy Subjects</condition>
  <condition>Part II (MAD) - Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (Day1) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses (Days 1, 15, 29) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses (Days 1, 15, 29) of MEDI3506 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses (Days 1, 15, 29) of MEDI3506 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI3506</intervention_name>
    <description>Single doses of MEDI3506 for SAD
Multiple doses of MEDI3506 for MAD</description>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_label>SAD Cohort 6</arm_group_label>
    <arm_group_label>SAD Cohort 7</arm_group_label>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single doses of placebo for SAD
Multiple doses of placebo for MAD</description>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_label>SAD Cohort 6</arm_group_label>
    <arm_group_label>SAD Cohort 7</arm_group_label>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Part I (SAD)

          1. Healthy volunteers age 18 through 55 years at the time of consent.

          2. Non-smokers, healthy current smokers, and ex-smokers are permitted.

          3. Pre-bronchodilator FEV1 ≥80% Predicted .

          4. BMI of 19.0 through 32.0 kg/m2 at screening.

          5. Current history of mild atopy.

        Inclusion Criteria Part II (MAD)

          1. Age 40 through 80 years at the time of screening.

          2. BMI of 19.0 through 35.0 kg/m2 at screening.

          3. Normal echocardiographic assessment within a year prior to randomisation

          4. Documented history of COPD with a post-bronchodilator FEV1/FVC &lt;0.70 and a
             post-bronchodilator FEV1 ≥50% predicted at screening.

          5. Clinically stable and free from an acute exacerbation of COPD for 8 weeks prior to Day
             1

          6. Current smoker with a tobacco history of ≥10 pack-years

        Exclusion Criteria Part I (SAD)

          1. Concurrent enrollment in another clinical study involving an investigational
             treatment.

          2. Received administration of and investigational drug or participated in a device trial
             within months, prior to screening (Visit 1)

          3. Subject is a participating investigator, sub-investigator, study coordinator or
             employee of the participating site, or is a first-degree relative of the
             aforementioned.

          4. Any active medical or psychiatric condition or other reason which, in the opinion of
             the investigator or medical monitor, may compromise the safety of the subject in the
             study or interfere with evaluation of the investigational product or reduce the
             subject's ability to participate in the study.

          5. Any clinically relevant abnormal findings on physical examination of the
             cardiovascular system including ECG and vital signs at screening or randomization

          6. Abnormal vital signs, after 10 minutes supine rest

        Exclusion Criteria Part II (MAD)

          1. Participation in an investigational drug or device trial within 30 days or 5
             half-lives, whichever time period is longer, prior to screening.

          2. Subject is a participating investigator, sub-investigator, study coordinator, or
             employee of the participating site, or is a first-degree relative of the
             aforementioned.

          3. Any active medical or psychiatric condition or other reason that, in the opinion of
             the investigator, would interfere with evaluation of the investigational product or
             interpretation of subject safety or study results. This includes, but is not limited
             to:

          4. Uncontrolled diabetes

          5. Hypertension during the screening period

          6. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart
             failure

          7. Clinically significant Aortic stenosis

          8. Pulmonary Arterial Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB, FFPM, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI3506</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical Study Report</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

